A Phase 3 interventional study of GFF MDI (PT003) and GP MDI (PT001) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Pearl Therapeutics, Inc.. Completed at 114 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 7th largest by enrollment, is one of 5 that started in 2013, is one of 33 in phase 3, and was the 33rd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,615 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 18th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2013, is one of 76 in phase 3, and was the 133rd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001), and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FF MDI administered as two puffs BID
Drug: FF MDI (PT005)
GP MDI administered as two puffs BID
Drug: GP MDI (PT001)
GFF MDI administered as two puffs BID
Drug: GFF MDI (PT003)
Inhaled placebo administered as two puffs BID
Drug: Placebo
Drug pages: Glycopyrrolate · Formoterol
GFF MDI administered as two puffs BID
Also known as: glycopyrrolate/formoterol fumarate metered-dose inhaler, (GFF MDI)
GP MDI administered as two puffs BID
Also known as: glycopyrrolate metered dose inhaler (GP MDI)
FF MDI administered as two puffs BID
Also known as: formoterol fumarate metered dose inhaler (FF MDI)
Change From Baseline in Morning Pre-dose Trough FEV1
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.
Time frame: At Week 24
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.
Time frame: Over 24 weeks
Peak FEV1
Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24
Time frame: At week 24
St. George Respiratory Questionnaire (SGRQ) Score
Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
Time frame: 24 weeks
Rescue Ventolin HFA Use
Change from baseline in average daily rescue Ventolin HFA use over 24 weeks
Time frame: 24 weeks
Onset of Action as Assessed by FEV1
Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant
Time frame: Day 1
Conducted at 140 sites throughout the United States from July 2013 - February 2015. Study participation was a maximum of 32 weeks.
| Milestone | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Started | 439 | 440 | 512 | 224 |
| Completed | 346 | 365 | 432 | 165 |
| Not completed | 93 | 75 | 80 | 59 |
| Withdrew: Protocol violation | 6 | 2 | 2 | 1 |
| Withdrew: Physician decision | 7 | 5 | 2 | 4 |
| Withdrew: Lost to follow-up | 8 | 9 | 8 | 4 |
| Withdrew: Withdrawal by subject | 28 | 21 | 29 | 15 |
| Withdrew: Protocol-specified criteria | 15 | 15 | 10 | 7 |
| Withdrew: Lack of efficacy | 3 | 8 | 4 | 7 |
| Withdrew: Adverse event | 21 | 14 | 23 | 19 |
| Withdrew: Administrative reasons | 5 | 1 | 2 | 2 |
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.
| Liters | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 | 0.061 (0.039 to 0.082) | 0.063 (0.041 to 0.084) | 0.116 (0.097 to 0.136) | 0.013 (-0.018 to 0.044) |
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.
| Liters | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks | 0.080 (0.064 to 0.095) | 0.082 (0.067 to 0.097) | 0.137 (0.123 to 0.151) | 0.008 (-0.014 to 0.030) |
Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24
| Liters | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Peak FEV1 | 0.268 (0.244 to 0.292) | 0.223 (0.199 to 0.247) | 0.350 (0.328 to 0.371) | 0.083 (0.048 to 0.117) |
Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
| Scores on a scale | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| St. George Respiratory Questionnaire (SGRQ) Score | -2.3 (-3.5 to -1.1) | -2.2 (-3.4 to -1.0) | -3.0 (-4.1 to -1.8) | -1.2 (-3.0 to 0.5) |
Change from baseline in average daily rescue Ventolin HFA use over 24 weeks
| Puffs / Day | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Rescue Ventolin HFA Use | -0.7 (-0.9 to -0.5) | -0.4 (-0.6 to -0.3) | -1.0 (-1.2 to -0.8) | 0.0 (-0.2 to 0.3) |
Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant
| Liters | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| 5 min post dose | 0.175 (0.163 to 0.188) | 0.052 (0.040 to 0.065) | 0.192 (0.180 to 0.204) | 0.006 (-0.012 to 0.024) |
| 15 min post dose | 0.212 (0.199 to 0.225) | 0.109 (0.096 to 0.122) | 0.237 (0.225 to 0.249) | 0.022 (0.003 to 0.040) |
Collected over Adverse events (AEs) and Serious Adverse Events (SAEs) will be collected from the time the subject signs the informed consent form up to 14 days following the last dose of study drug.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF MDI (PT005) | — | 37/438 (8.4%) | 21/438 (4.8%) |
| GP MDI (PT001) | — | 37/439 (8.4%) | 12/439 (2.7%) |
| GFF MDI (PT003) | — | 36/510 (7.1%) | 22/510 (4.3%) |
| Placebo MDI | — | 15/223 (6.7%) | 10/223 (4.5%) |
| Event | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 8/438 | 9/439 | 8/510 | 4/223 |
| PneumoniaInfections and infestations | 4/438 | 4/439 | 2/510 | 3/223 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/438 | 0/439 | 1/510 | 2/223 |
| Myocardial infarctionCardiac disorders | 0/438 | 0/439 | 0/510 | 2/223 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/438 | 1/439 | 3/510 | 0/223 |
| Atrial fibrillationCardiac disorders | 0/438 | 2/439 | 3/510 | 0/223 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/438 | 0/439 | 0/510 | 1/223 |
| Small intestinal obstructionGastrointestinal disorders | 2/438 | 0/439 | 0/510 | 0/223 |
| Non-cardiac chest painGeneral disorders | 2/438 | 0/439 | 1/510 | 0/223 |
| Cardiac failure congestiveCardiac disorders | 0/438 | 2/439 | 0/510 | 0/223 |
| Event | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/438 | 12/439 | 22/510 | 10/223 |
5 subjects participated in more than one Phase 3 Pearl study (a protocol violation) and had overlapping treatment exposure - these subjects were removed from the ITT and safety populations; 1 subject participated in more than one Phase 3 Pearl study but did not have overlapping treatment exposure - this subject was removed from the ITT population
| Age, Continuous(Years) | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI | Total |
|---|---|---|---|---|---|
| Mean | 62.6 ± 7.8 | 62.8 ± 8.4 | 62.8 ± 8.2 | 64.2 ± 8.7 | 62.9 ± 8.3 |
| Sex: Female, Male(Participants) | FF MDI (PT005) | GP MDI (PT001) | GFF MDI (PT003) | Placebo MDI | Total |
|---|---|---|---|---|---|
| Female | 190 | 197 | 238 | 98 | 723 |
| Male | 247 | 242 | 272 | 125 | 886 |
Showing the first 100 of 114 sites. Choose a country and city above to see the rest.
The record gives a start of Jul 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →